Evaluation of Serum Endothelial Cell Specific Molecule-1 (Endocan) Levels as a Biomarker in Patients With Pulmonary Thromboembolism

Abstract

The aim of this study was to investigate the relationship between pulmonary thromboembolism (PTE) and serum endocan levels. The study included 46 patients with a diagnosis of PTE and control group (25 healthy individuals). Serum endocan levels in all participants' blood samples were measured. The average age of the individuals was 61.76±16.39 years. There was a significant difference in the serum endocan levels between the patients and those of the control group [321.93ng/l (111.35-2511.33) and 192.77ng/l (118.30-309.02), respectively; P<0.030]. The serum endocan levels in the submassive [469.41ng/l (258.13-800.54)] and the massive PTE groups [719.18ng/l (319.84-2511.33)] were statistically higher than those in the control group [192.77ng/l (118.30-309.02)] (P<0.001 and P<0.001, respectively). In addition, there was a statistically significant difference between the serum endocan levels of the nonmassive PTE group [188.57ng/l (111.35-685.56)] and the submassive PTE group (P<0.01). The serum endocan levels correlated with the international normalization ratio (INR), right ventricular dilatation (RVD) and SBP (r=0.418, P=0.004; r=0.659, P<0.001; r=-0.425, P=0.003, respectively). In conclusion, serum endocan levels can be considered a practicable biomarker to determine the severity of PTEs and follow-up thrombolytic therapy. © 2014 Wolters Kluwer Health Lippincott Williams & Wilkins.